Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Dr Ellis Highlights Novel Approach That May Boost Prostate Cancer Immunotherapies

04/28/2021

Leigh Ellis, PhD, discusses efforts of Cedars-Sinai researchers to discover new ways to alter tissues surrounding prostate tumors to help the body fight cancer.

Leigh Ellis, PhD, discusses...

04/28/2021

Oncology

Videos

Dr Tagawa Reviews the Role of ADT in COVID-19 in Prostate Cancer

03/09/2021

Scott Tagawa, MD, MS FACP, discusses the impact of ADT on the clinical course of COVID-19 in patients with prostate cancer.

Scott Tagawa, MD, MS FACP,...

03/09/2021

Oncology

Podcasts

Dr Saad Highlights Results Following the ACIS Study

02/20/2021

Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.

Fred Saad, MD, discusses the...

02/20/2021

Oncology

Videos

Dr Feng Discusses Molecular Determinants of Response to APA in nmCRPC

02/20/2021

Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.

Felix Feng, MD, talks about...

02/20/2021

Oncology

Interview

Dr Cohen Reveals CCR Score May Offer ADT-Free Therapy in Higher-Risk Prostate Cancer

02/16/2021

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.

Todd Cohen, MD, highlights how...

02/16/2021

Oncology

Videos

Dr Tward Discusses CCR Scores Accurately Guiding Treatment for Prostate Cancer

02/16/2021

Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.

Jonathan Tward, MD, discusses...

02/16/2021

Oncology

Videos

Dr Chi Discusses Final Results Following the TITAN Study

02/16/2021

Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.

Kim Chi, MD, discusses final...

02/16/2021

Oncology

Videos

Alexandra Sokolova, MD, Talks Germline Testing for Veterans With Metastatic Prostate Cancer

12/28/2020

Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.

Dr Sokolova highlights a...

12/28/2020

Oncology

Videos

Alexandra Sokolova, MD, Provides a Commentary on the GENTleMEN Study

10/28/2020

Dr Sokolova discusses the GENTleMEN study and important differences between somatic and germline testing for patients with prostate cancer.

Dr Sokolova discusses the...

10/28/2020

Oncology

Interview

Is the HULLK Key to Controlling Prostate Cancer Growth?

10/10/2019

Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.

Daniel Gioeli, PhD, and...

10/10/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology